Healthcare / BiotechnologyNasdaqGM
$4.82
+0.29 (+6.40%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-84.7M · quality 66.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
43/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.8B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-297.5%
↓Gross Margin
N/A
•Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+159.9%
FCF CAGR
—
FCF margin
-2776.8%
FCF / Net income
0.17x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $4.1M · net income $-660.0M · FCF $-113.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $4.1M | $4.1M | $308000.00 | $314000.00 | $233000.00 |
| Net Income | $-660.0M | $-660.0M | $-149.3M | $-40.2M | $-152.4M |
| EBITDA | $-657.7M | $-657.7M | $-144.8M | $-36.3M | $-134.1M |
| EPS | -2.91 | -2.91 | -0.93 | -0.25 | -0.98 |
| Operating Margin | -2772.0% | -2772.0% | -33170.8% | -39180.3% | -61987.1% |
| Net Margin | -16142.0% | -16142.0% | -48464.0% | -12810.2% | -65401.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.21 | 0.08 | 0.06 |
| Current Ratio | 10.02 | 10.02 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-113.5M | $-113.5M | $-82.5M | $-84.7M | $-105.5M |
| Returns | |||||
| ROE | -297.5% | -297.5% | -128.4% | -16.6% | -58.4% |
| Valuation | |||||
| P/B | 4.92 | 4.92 | 2.44 | 1.07 | 1.09 |
| Growth & Yield | |||||
| Revenue Growth | 1227.6% | 1227.6% | -1.9% | 34.8% | — |
| EPS Growth | -212.9% | -212.9% | -272.0% | 74.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+108.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.93 → -2.91
Residual
+108.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.